
Anika Therapeutics Inc ANIK.OQ ANIK.O is expected to show a fall in quarterly revenue when it reports results on May 9 for the period ending March 31 2025
The Bedford Massachusetts-based company is expected to report a 30.7% decrease in revenue to $28.067 million from $40.52 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Anika Therapeutics Inc is for a loss of 14 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 1,866.7% in the last three months.
Wall Street's median 12-month price target for Anika Therapeutics Inc is $21.00, above its last closing price of $14.08.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.51 | -0.29 | -1.50 | Missed | -408.5 |
Sep. 30 2024 | -0.04 | -0.01 | -0.25 | Missed | -1,566.7 |
Jun. 30 2024 | 0.07 | 0.05 | -0.01 | Missed | -121.4 |
Mar. 31 2024 | -0.21 | -0.19 | -0.31 | Missed | -66.1 |
Dec. 31 2023 | -0.26 | -4.30 | Missed | -1,532.9 | |
Sep. 30 2023 | -0.38 | -0.37 | -0.45 | Missed | -20.5 |
Jun. 30 2023 | -0.27 | -0.27 | -0.19 | Beat | 29.6 |
Mar. 31 2023 | -0.33 | -0.30 | -0.47 | Missed | -56.7 |
This summary was machine generated May 7 at 12:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)